Methods of treating disseminated intravascular coagulation...

Details Methods of treating disseminated intravascular coagulation... Methods of treating disseminated intravascular coagulation...

2006-11-14

2006-11-14

Gambel, Phillip (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100, C424S133100, C424S141100, C424S158100, C530S387100, C530S387300, C530S388100, C530S388200, C530S388230

Reexamination Certificate

active

07135178

ABSTRACT:
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful for therapy of TNFα-mediated pathologies and conditions, including vascular inflammatory pathologies.

REFERENCES:
patent: 4603106 (1986-07-01), Cerami et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4822776 (1989-04-01), Cerami et al.
patent: 5075236 (1991-12-01), Yone et al.
patent: 5223395 (1993-06-01), Gero
patent: 5231024 (1993-07-01), Moeller et al.
patent: 5360716 (1994-11-01), Ohmoto et al.
patent: 5436154 (1995-07-01), Barbanti et al.
patent: 5654407 (1997-08-01), Boyle et al.
patent: 5658570 (1997-08-01), Newman et al.
patent: 5700788 (1997-12-01), Mongelli et al.
patent: 5730975 (1998-03-01), Hotamisligil et al.
patent: 5741488 (1998-04-01), Feldman et al.
patent: 5750105 (1998-05-01), Newman et al.
patent: 5776947 (1998-07-01), Kroemer et al.
patent: 5919452 (1999-07-01), Le et al.
patent: 5959087 (1999-09-01), Rathjen et al.
patent: 6015558 (2000-01-01), Hotamisligil et al.
patent: 6172202 (2001-01-01), Marcucci et al.
patent: 6194451 (2001-02-01), Alpegiani et al.
patent: 6309640 (2001-10-01), Cerami et al.
patent: 6419927 (2002-07-01), Cerami et al.
patent: 6914128 (2005-07-01), Salfeld et al.
patent: 0 212 489 (1987-03-01), None
patent: 0 218 868 (1987-04-01), None
patent: 0 260 610 (1988-03-01), None
patent: 0 288 088 (1988-10-01), None
patent: 0 288 088 (1988-10-01), None
patent: 0 308 378 (1989-03-01), None
patent: 0 350 690 (1990-01-01), None
patent: 0 351 789 (1990-01-01), None
patent: 0 351 789 (1990-01-01), None
patent: 0 380 068 (1990-08-01), None
patent: 0 393 438 (1990-10-01), None
patent: 0 398 327 (1990-11-01), None
patent: 0 412 486 (1991-02-01), None
patent: 0 433 900 (1991-06-01), None
patent: 0 453 898 (1991-10-01), None
patent: 0 526 905 (1993-02-01), None
patent: 0 585 705 (1994-03-01), None
patent: 0 614 984 (1994-09-01), None
patent: 0 101 681 (1994-12-01), None
patent: 0 663 836 (1995-07-01), None
patent: 0 486 526 (2001-03-01), None
patent: 61-047500 (1986-03-01), None
patent: 02-227095 (1990-09-01), None
patent: WO 89/08460 (1989-09-01), None
patent: 90/00902 (1990-02-01), None
patent: WO 90/01950 (1990-03-01), None
patent: WO91/02078 (1991-02-01), None
patent: WO 91/04054 (1991-04-01), None
patent: 91/09967 (1991-07-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO92/01059 (1992-01-01), None
patent: WO 92/01472 (1992-02-01), None
patent: WO 92/16553 (1992-03-01), None
patent: WO92/07076 (1992-04-01), None
patent: WO 92/02190 (1992-06-01), None
patent: WO 92/11383 (1992-07-01), None
patent: WO 92/13095 (1992-08-01), None
patent: WO 93/02108 (1993-02-01), None
patent: WO 93/11236 (1993-06-01), None
patent: WO 94/08609 (1994-04-01), None
patent: WO 94/08619 (1994-04-01), None
U.S. Appl. No. 10/227,488, filed Aug. 23, 2002, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight and Scott Siegel.
Yan, L. et al., “Preparation and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor Alpha”,Chinese J. Biotechnology, 7(2) :121-126 (1991).
Mateo, C. et al., “Removal of Amphipathic Epitopes from Genetically Engineered Antibodies: Production of Modified Immunoglobulins with Reduced Immunogenicity”,Hybridoma, 19(6) :463-471 (2000).
Paul, W.E. (Ed.),Fundamental Immunology, 3rdEdition, Pub. Raven Press Ltd., pp. 292-293 (1993).
Borrebaeck, C.A.K. (Ed.),Antibody Engineering, 2ndEdition,Pub. Oxford University Press, p. 291 (1995).
Socher, S. et al., “Antibodies against amino acids 1-15 of tumor necrosis factor block its binding to cell-surface receptor”,Proc. Natl. Acad. Sci., USA 84:8829-8833 (1987).
Goh, C., “Tumour Necrosis Factors in Clinical Practice”,Annals of the Academy of Medicine, 19(2) :235-239 (1990).
Beutler, B. et al., “Identity of tumour necrosis factor and the macrophage-secreted factor cachectin,”Nature, 316:552-554 (1985).
Beutler, B. et al., “Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin,”Science, 229:869-871 (1985).
Morrison, Sherie L., “Transfectomas Provide Novel Chimeric Antibodies,”Science, 229:1202-1207 (1985).
Liang, Chi-Ming et al., “Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin,”Biochem.&Biophy. Res. Comm., 137(2) :847-854 (1986).
Hirai, Makoto et al., “Production and characterization of monoclonal antibodies to human tumor necrosis factor,”J. of Immun. Methods, 96:57-62 (1987).
Piguet, Pierre-Francois et al., “Tumor Necrosis Factor/Cachectin is an Effector of Skin and Gut Lesions of the Acute Phase of Graft-vs.-Host Disease,”J. Exp. Med., 166:1280-1289 (1987).
Meager, Anthony et al., “Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF),”Hybridoma, 6(3) :305-311 (1987).
Fendly, Brian M. et al., “Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor,”Hybridoma, 6(4) :359-370 (1987).
Bringman, Timothy S. and Aggarwal, Bharat B., “Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Applications for Affinity Purification, Immunoassays, and as Structural Probes,”Hybridoma, 6 (5) :489-507 (1987).
Tracey, Kevin J. et al., “Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia,”Nature, 330:662-664 (1987).
Nagai, M. et al., “Antibody to tumor necrosis factor (TNF) reduces endotoxin fever,”Experientia, 44:606-607 (1988).
Shimamoto, Yoshinori et al., “Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock,”Immunology Letters, 17:311-318 (1988).
Di Giovine, Francesco, S. et al., “Tumour necrosis factor in synovial exudates,”Annals of the Rheumatic Diseases, 47:768-772 (1988).
Collins, M.S. et al., “Immunoprophylaxis of Polymicrobic Cellulitis with a Human Monoclonal Antibody Against Lipopolysaccharide Antigen ofPseudomonas aeruginosa,” Abstract E-63,Abstracts of Annual Meeting 1989.
Exley, A.R. et al., “Monoclonal Antibody (Mab) to Recombinant Human Tumour Necrosis Factor (rhTNF) in the Prophylaxis and Treatment of Endotoxic Shock in Cynomolgus Monkeys,”Medical Research Society, Abstract 184, p. 50 (1989).
Cross, A.S. et al., “Pretreatment with Recombinant Murine Tumor Necrosis Factor α/Cachectin and Murine Interleukin 1 α Protects Mice from Lethal Bacterial Infection,”J of Exp Med., 169:2021-2027 (1989).
Engelmann, Hartmut et al., “A Tumor Necrosis Factor-binding Protein Purified to Homogeneity from Human Urine Protects Cells from Tumor Necrosis Factor Toxicity,”J. of Bio. Chem., 264(20) :11974-11980 (1989).
Kawasaki, Hajime et al., “Analysis of Endotoxin Fever in Rabbits by Using a Monoclonal Antibody to Tumor Necrosis Factor (Cachectin),”Infection and Immunity, 57(10):3131-3135 (1989).
Fong, Yuman et al., “Antibodies to Cachectin/Tumor Necrosis Factor Reduce Interleukin 1β and Interleukin 6 Appearance During Lethal Bacteremia,”J. Exp. Med., 170:1627-1633 (1989).
Von Asmuth, E.J.U. et al., “Tumour Necrosis Factor Alpha (TNF-α) and Interleukin 6 in a Zymosan-Induced Shock Model,”Scand. J. Immunol., 32:313-319 (1990).
Herve, P. et al., “Monoclonal Anti TNF α Antibody for the Treatment of Severe Acute GvHD in Humans,” Abstract 3.25,Lymphoma Res.9:591 (1990).
Silva, Ayona T. et al., “Prophylactic and Therapeutic Effects of a Monoclonal Antibody to Tumor Necrosis Factor-α in Experimental Gram-Negative Shock,”J. of Infectious Diseases, 162:421-427 (1990).
Opal, Steven M. et al., “Efficacy of a Monoclonal Antibody Directed Against Tumor Necrosis Factor in Protecting Neutropenic

Affiliated with

Also associated with

Rating

Methods of treating disseminated intravascular coagulation... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating disseminated intravascular coagulation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating disseminated intravascular coagulation... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3684775